WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ:RGEN) today reported results for its first quarter ended March 31, 2012. Total revenue for the first quarter of 2012 was $12,824,000 compared to total revenue of $5,906,000 for the same period in 2011. Revenue growth for the quarter was driven by the Company’s expanded bioprocessing business, which generated $9,343,000 in product revenue compared to $3,151,000 for the same period in 2011. Royalty and research revenue for the first quarter of 2012, consisting primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia®, was $3,482,000, compared to $2,756,000 for the same period in 2011. The three-month period ended March 31, 2012 marks the first full fiscal quarter for which the Company is reporting consolidated financial results since its acquisition of Novozymes Biopharma Sweden AB (now Repligen Sweden AB) in December 2011.
